Back to Search Start Over

Tissue Damage in Radiation-Induced Oral Mucositis Is Mitigated by IL-17 Receptor Signaling.

Authors :
Saul-McBeth J
Dillon J
Lee A
Launder D
Kratch JM
Abutaha E
Williamson AA
Schroering AG
Michalski G
Biswas P
Conti SR 3rd
Shetty AC
McCracken C
Bruno VM
Parsai EI
Conti HR
Source :
Frontiers in immunology [Front Immunol] 2021 Jun 17; Vol. 12, pp. 687627. Date of Electronic Publication: 2021 Jun 17 (Print Publication: 2021).
Publication Year :
2021

Abstract

Oral mucositis (OM) is a treatment-limiting adverse side effect of radiation and chemotherapy. Approximately 80% of patients undergoing radiotherapy (RT) for head and neck cancers (HNC) develop OM, representing a major unmet medical condition. Our understanding of the immunopathogenesis of OM is limited, due in part to the surprising paucity of information regarding healing mechanisms in the oral mucosa. RNAseq of oral tissue in a murine model that closely mimics human OM, showed elevated expression of IL-17 and related immune pathways in response to head and neck irradiation (HNI). Strikingly, mice lacking the IL-17 receptor (IL-17RA) exhibited markedly more severe OM. Restoration of the oral mucosa was compromised in Il17ra <superscript>-/-</superscript> mice and components associated with healing, including matrix metalloproteinase 3, 10 and IL-24 were diminished. IL-17 is typically associated with recruitment of neutrophils to mucosal sites following oral infections. Unexpectedly, in OM the absence of IL-17RA resulted in excessive neutrophil recruitment and immunopathology. Instead, neutrophil activation was IL-1R-driven in Il17ra <superscript>-/-</superscript> mice. Blockade of IL-1R and depletion of neutrophils lessened the severity of damage in these mice. Overall, we show IL-17 is protective in OM through multiple mechanisms including restoration of the damaged epithelia and control of the neutrophil response. We also present a clinically relevant murine model of human OM to improve mechanistic understanding and develop rational translational therapeutics.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Saul-McBeth, Dillon, Lee, Launder, Kratch, Abutaha, Williamson, Schroering, Michalski, Biswas, Conti, Shetty, McCracken, Bruno, Parsai and Conti.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
34220843
Full Text :
https://doi.org/10.3389/fimmu.2021.687627